Hydroxychloroquine is considered one of the most promising drugs to fight the new coronavirus, but according to data, the antimalarial drug does not help the new coronavirus, so resistance to the virus is increasing. It is reported that the drug for various reasons in March has been widely reported. Anecdotal evidence suggests that some patients with new coronary pneumonia recover after taking the drug.
Subsequent studies have shown that the drug has serious side effects and can be fatal to a patient’s heart, prompting researchers in Brazil and France to halt its research. The largest hydroxychloroquine study to date has been funded in the United States, which showed that the drug did not help with the treatment of new coronary pneumonia.
Researchers from New York Presbyterian Hospital and Irving Medical Center at Columbia University in New York conducted the study, which was funded by the National Institutes of Health.
Nearly 60 percent of the 1,376 coronavirus patients in the study took the drug within 48 hours. As a result, the researchers found that these patients were more severe than those who did not take hydroxychloroquine. However, this is an observational study, which means that doctors only analyzed the evolution of these cases during hospital treatment without managing the actual treatment of patients. Researchers need randomized clinical trials to obtain definitive evidence of whether hydroxychloroquine is helpful to patients with neo-coronary pneumonia.
To determine the potential effectiveness of the drug, the New York State Department of Health and the University of Albany are conducting a second observational study. The researchers will look at medical records of the death or recovery of patients with new coronary pneumonia and look at the prescription drugs they use.